Gilead just made a $4.9 billion bet on cancer-drug maker Forty Seven, whose stock skyrocketed 62%
- Gilead Sciences on Monday said it plans to buy cancer-drug maker Forty Seven in a $4.9 billion deal.
- The news sent Forty Seven's stock up as much as 62% during regular trading.
- The deal is the latest to add to Gilead's presence in cancer immunotherapy, an approach to treating cancer that harnesses the body's immune system.
- Visit Business Insider's homepage for more stories.
View all Offers
- 20% OFF
iQOO Z5 5G (Mystic Space, 8GB RAM, 128GB Storage) | Snapdragon 778G 5G Processor | 5000mAh Battery | 44W FlashCharge | Rs.1000 Coupon Discount₹ 23990₹ 29990Buy On
- 23% OFF
Redmi 9 (Sky Blue, 4GB RAM, 64GB Storage) | 2.3GHz Mediatek Helio G35 Octa core Processor₹ 8499₹ 10999Buy On
- 26% OFF
Samsung Galaxy M52 5G (ICY Blue, 6GB RAM, 128GB Storage) Latest Snapdragon 778G 5G | sAMOLED 120Hz Display₹ 25999₹ 34999Buy On
- 17% OFF
Samsung Galaxy M21 2021 Edition (Arctic Blue, 4GB RAM, 64GB Storage) | FHD+ sAMOLED | 6 Months Free Screen Replacement for Prime (SM-M215GLBDINS)₹ 11999₹ 14499Buy On
- 17% OFF
Redmi Note 10 Pro Max (Glacial Blue, 6GB RAM, 128GB Storage) -108MP Quad Camera|120Hz Super Amoled Display₹ 18999₹ 24999Buy On
Gilead Sciences is buying drugmaker Forty Seven in a $4.9 billion deal, the company said Monday.
Gilead will pay $95.50 a share in cash for Forty Seven, the company said. Forty Seven, which is developing treatments for certain kinds of blood cancers, soared as much as 62% in regular trading on Monday.
Menlo Park, California-based Forty Seven's farthest-along experimental treatment is magrolimab, which is being studied for use in certain blood cancers with the chemotherapy azacitidine. The drug acts by blocking the CD47 signal on cancer cells, leaving the body's immune system more free to attack them.
Best known for its treatments for conditions like HIV and hepatitis C, Foster City, California-based Gilead has spent the past few years bulking up its presence in cancer drug development. In 2017, the company bought cancer-immunotherapy companyKite Pharma in a $12 billion deal. Kite makes a treatment called Yescarta, which re-engineers the body's own cells to attack cancer cells.
Featured Digital Health Articles:
- Telehealth Industry: Benefits, Services & Examples
- Value-Based Care Model: Pay-for-Performance Healthcare
- Senior Care & Assisted Living Market Trends
- Smart Medical Devices: Wearable Tech in Healthcare
- AI in Healthcare
- Remote Patient Monitoring Industry: Devices & Market Trends
- A CryptoPunk NFT bought for $74 resurfaced after four years and just sold for $2 million
- Best DIY wallpapers to revamp your house
- India's largest car maker loses nearly two thirds of its profit to chip shortage
- New Range Rover: Check out expected price in India, features and other details
- Softbank will make $250 million by selling a fifth of its stake in Policybazaar